The human body hosts trillions of microorganisms — bacteria, viruses, and fungi — that collectively form the microbiome. Research over the past decade has shown that the microbiome plays active roles in cancer development and progression, with distinct microbial signatures associated with different cancer types. Pancreatic cancer patients have measurably different gut and tumor microbiomes compared to healthy people.
The challenge has been measuring these microbial differences non-invasively. Fecal samples capture gut bacteria but not the systemic picture. This study focused on extracellular vesicles (EVs) — tiny particles released by bacteria that circulate in the bloodstream — as a source of microbial biomarkers from a simple blood draw. EVs from bacteria carry stable microbial genetic material that can be sequenced and analyzed.
Blood samples were collected from 38 pancreatic cancer patients and 51 healthy controls. Extracellular vesicles were isolated from the serum and their microbial DNA was sequenced and classified at two taxonomic levels: phylum (broad bacterial groups) and genus (more specific groups). This generated a rich dataset of microbial abundances for each participant.
Two statistical marker selection methods were applied: LASSO (which mathematically selects the most informative features from large datasets by penalizing unimportant variables to zero) and stepwise selection (which adds and removes variables iteratively based on statistical criteria). The resulting candidate marker sets were then used to train four machine learning models: logistic regression (LR), random forest (RF), support vector machine (SVM), and deep neural network (DNN).
At the phylum level, the DNN model using three markers — Verrucomicrobia, Actinobacteria, and Proteobacteria — achieved a test AUC of 0.959. These three broad bacterial groups showed markedly different relative abundances in pancreatic cancer patients compared to healthy controls.
At the more granular genus level, DNN with 11 markers selected by LASSO reached a test AUC of 0.961. The 11 bacteria included Akkermansia (known for gut barrier protection), Pseudomonas, Ruminococcaceae UCG-013, and others — a mix of species that together distinguish PDAC patients with remarkable accuracy.
Both AUC values above 0.95 indicate near-perfect discrimination between cancer patients and healthy controls, substantially better than CA19-9 alone. The DNN model consistently outperformed logistic regression, random forest, and SVM, suggesting the microbial patterns are complex enough to benefit from deep learning's ability to detect non-linear relationships.
The potential clinical application is compelling: a blood draw, EV isolation, and microbiome sequencing could serve as a minimally invasive screening test for pancreatic cancer, particularly in high-risk populations (people with new-onset diabetes, family history, or hereditary mutations). Early detection when tumors are still small dramatically improves surgical eligibility and survival.
Compared to current alternatives — CT scans (radiation exposure, costly), endoscopic ultrasound (invasive, specialized equipment), or CA19-9 (poor accuracy) — a blood-based microbiome test could be deployed much more broadly and repeated over time to track disease emergence.
With AUCs above 0.95 in this pilot study, microbiome markers from serum EVs show extraordinary promise as non-invasive pancreatic cancer biomarkers. The next essential step is validation in larger, diverse, multi-center cohorts to confirm these results are generalizable and not influenced by diet, geography, or medication differences between the small study groups.
If validated, this approach would represent a paradigm shift in pancreatic cancer screening — using the body's microbial ecosystem as a surveillance network for one of medicine's deadliest diseases.